Corvus Pharma Q2 EPS $(0.07) Beats $(0.12) Estimate
Portfolio Pulse from Benzinga Newsdesk
Corvus Pharma (NASDAQ:CRVS) reported a Q2 EPS loss of $(0.07), beating the analyst estimate of $(0.12) by 41.67%. This represents a 50% improvement over the $(0.14) loss per share from the same period last year.
August 06, 2024 | 8:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Corvus Pharma reported a Q2 EPS loss of $(0.07), which is significantly better than the analyst estimate of $(0.12). This also marks a 50% improvement over the same period last year.
The better-than-expected EPS and significant year-over-year improvement are likely to positively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100